New Answers On Macular Degeneration; Important Questions For Comparative Effectiveness Research
May 6th, 2011
 by
Steven Pearson
|
On April 28th, the New England Journal of Medicine published the results of a study that compared two drugs head-to-head for the treatment of age-related macular degeneration (AMD), the leading cause of legal blindness in the United States. The two drugs, Ranibizumab (Lucentis) and Bevacizumab (Avastin), are very similar molecules and are both meant to... Read the rest of this entry »
